An FDA import alert puts your firm or product on a Red List, so every shipment can be detained at the port without examination until you prove it complies. Removal is not automatic: FDA has to see that the cause was fixed and that future shipments will comply. We build that case, from root cause and corrective actions to clean entries, lab evidence and the petition.
Start with the alert number. Send us the import alert, your entry numbers and any Notices of FDA Action. We confirm your list status and what FDA will need before you spend money on testing or shipments.
Get a Case ReviewYou can check status yourself in the FDA Import Alert database. In most cases, being published on the alert is the only notice FDA gives (FDA Import Alert FAQ).
| List | What it means | Effect on shipments |
|---|---|---|
| Red List | Firms, products or countries that met the criteria for DWPE | Shipments can be detained without examination |
| Yellow List | Firms or products listed for heightened attention under the alert | Subject to DWPE under that alert, per FDA |
| Green List | Firms or products that met the criteria for exemption from DWPE | Exempt from DWPE under that alert |
Definitions follow FDA Import Alerts. On a country-wide alert, getting onto the Green List is how a firm ships without DWPE.
FDA's framework is in RPM Chapter 9-8; the specific alert's Guidance adds the details. Want the full process explained? Read how to remove an FDA import alert.
FDA removal guidance says FDA considers the totality of evidence, and one passing test rarely proves a production problem is fixed.
Need samples pulled and tested for a detained entry? Our sister company, FDA Detention Sampling, coordinates sample collection, chain of custody and testing with LAAF-accredited laboratories nationwide. Call +1 (786) 561-3726.
Pesticides, pathogens, filth, labeling and FSVP alerts.
CGMP, unapproved drug and API alerts handled by CDER.
Registration, listing, 510(k) and quality system alerts.
What detention without physical examination means.
Our sister company for detention sampling and lab testing.
Help with a single shipment FDA is holding now.
Processed foods with illegal pesticide residues.
Foods with lead, arsenic, cadmium or mercury.
Foods with Salmonella, such as spices, sesame, candy and nuts.
Foods and supplements with illegal or undeclared colors.
Canned and acidified foods without filed processes.
Foods with aflatoxin and other mycotoxins.
Fresh produce packed or held under insanitary conditions.
Human foods with insect, rodent or mold filth.
Farmed seafood with unapproved drug residues.
Seafood with nitrofuran residues.
Foods and supplements with hidden drug ingredients.
Germanium supplements for human use.
Supplements with aristolochic acid.
U.S. importers not in compliance with FSVP.
Foods with undeclared major food allergens.
Misbranded imported foods and supplements.
Foods with undeclared added sulfites.
Foods with unsafe additives such as cyclamate.
Ready-to-eat foods made under insanitary conditions.
Seafood with Salmonella.
Supplements from firms not meeting GMP.
Kratom supplements and bulk ingredients.
Supplements with unsafe new dietary ingredients.
Canned and acidified foods that did not answer FDA process requests.
Canned and acidified foods with inadequate process control.
Economically motivated adulteration, such as diluted honey.
Chemical contamination, such as PFAS in clams.
Chemical contamination from insanitary conditions, such as cesium-137.
Natural toxins, such as soursop seed and toxic morels.
Foods with melamine and melamine analogs.
Products labeled ginseng that are not Panax.
Supplements with ephedrine alkaloids.
Seafood with chloramphenicol.
Coconut products with microbiological contamination.
Cheese with Salmonella, Listeria or pathogenic E. coli.
Raw agricultural products with pesticide residues.
Countrywide pesticide detention of raw produce.
Countrywide pesticide detention of processed foods.
Ready-to-eat produce with Salmonella, E. coli O157:H7 or Shigella findings.
Seafood processors not in compliance with seafood HACCP.
We review your alert, list status and entry history, build the root-cause and corrective-action record, plan the clean-entry and lab evidence, and prepare and submit the removal petition. We are an independent compliance firm, not FDA or a law firm, and we never guarantee FDA's decision.
Contact our specialists, email info@fdaregistrationassistance.com, or call +1 (928) 275-8333. Removal guide · DWPE explained · Contact.
Get a Case ReviewFDA Registration Assistance is a private consulting firm, not FDA or any government agency. FDA registration is not FDA approval, clearance or certification.
An FDA Import Alert is agency guidance used to notify FDA staff, the import community, and the public about products, firms, countries/areas, or other categories that appear to violate FDA requirements and may be subject to specified import action, including Detention Without Physical Examination.
DWPE means Detention Without Physical Examination. When a product is subject to DWPE under an Import Alert, FDA can detain the shipment based on the alert without first physically examining that particular shipment.
A product subject to DWPE can be detained and may be refused unless the importer overcomes the appearance of the violation. FDA's Guidance section for the specific Import Alert explains the evidence that may be appropriate for release of an individual entry.
Search the FDA Import Alert database by firm name, product, country or alert number; FDA states it is updated in real time. In most cases FDA does not send a separate notice, because publication on the alert serves as notification (FDA Import Alert FAQ). A Notice of FDA Action citing an import alert on a detained entry is another sign.
FDA defines the Red List as firms, products, and/or countries that have met the criteria for DWPE under an Import Alert.
FDA describes Yellow List entities as subject to intensified surveillance; FDA's current Import Alerts page also states that firms/products appearing on a Yellow List are subject to DWPE under that alert.
FDA defines the Green List as firms, products, and/or countries that have met the criteria for exemption from DWPE under an Import Alert.
Start with the Guidance section of the specific Import Alert. FDA's general removal guidance says the petition should be tailored to the alert, product, problem, and requested removal action and may include investigation findings, corrective actions, preventive measures, and objective evidence supporting future compliance.
No. FDA removal guidance lists 5 clean shipments as one example of evidence and says FDA considers the totality of evidence. Some specific Import Alerts expressly require or recommend a minimum of five or another number of compliant commercial entries. The current Guidance section of the specific Import Alert controls the strategy. For a step-by-step walkthrough, see how to remove an import alert.
FDA's Import Alert FAQ says there is no exact universal quantity or timeframe for what counts as a routine commercial entry, but the entries should occur over a reasonable time and reflect normal shipping patterns.
Usually not by itself. Release of an individual entry and removal from DWPE are separate issues. The removal request must satisfy the evidence expectations of the specific Import Alert and demonstrate that the condition giving rise to the appearance of violation has been addressed.
Yes, depending on the alert and violation. FDA states that when a shipment is subject to DWPE, the importer or consignee has the right to provide testimony or evidence to demonstrate that the product does not have the violation listed in the Import Alert. The Guidance section explains what may be needed.
Common evidence can include the firm's investigation, root-cause findings, corrective actions, preventive measures, production or quality records, clean commercial entries, third-party laboratory reports, audits, inspection evidence, registrations/listings, labels, or other information relevant to the violation and specific alert.
FDA's current Import Alert pages commonly state that a firm and/or a representative of the firm may petition for removal from DWPE. The appropriate representative and submission path should be confirmed from the specific alert.
FDA removal guidance currently directs most petitions to ImportAlerts2@fda.hhs.gov, but certain alerts require petitions to go directly to the Compliance Officer or another contact identified in that Import Alert's Guidance section. Drug alerts such as 66-40, for example, name a CDER contact.
FDA's current Import Alert removal instructions do not list a petition filing fee. Professional consulting, laboratory testing, audits, reconditioning, storage, demurrage, customs, or other case costs are separate and can vary.
FDA does not publish a guaranteed universal decision time for all Import Alert removal requests. Timing depends on the alert, program office, complexity, completeness of corrective evidence, whether FDA requests more information, and whether inspection or additional verification is necessary.
No. FDA determines whether the evidence is sufficient to change the DWPE status. A consultant can improve organization, identify missing evidence, prepare the submission, and support follow-up, but cannot guarantee the agency's decision or timing.
Individual-entry release focuses on demonstrating that one shipment does not have the violation identified in the alert. Import Alert removal focuses on demonstrating that the underlying condition has been resolved so FDA can consider changing the firm's or product's ongoing DWPE status.
An Import Alert is an import-enforcement tool associated with DWPE. A Warning Letter communicates FDA's position about significant violations and requests corrective action. A company can be dealing with both at the same time, and resolving one does not automatically resolve the other.
No response deadline should be assumed without reading the actual letter. Many FDA Warning Letters request a response within 15 working days, but the firm should follow the deadline and instructions stated in the specific letter.
Yes. FDA maintains Import Alerts across multiple regulated product categories. The legal charge, evidence, responsible FDA program office, testing, registration/listing issues, and removal criteria can differ substantially by product category and specific alert.
No. RPM Chapter 9-8 provides the overall DWPE framework, but each Import Alert can have its own Guidance section, evidence expectations, responsible FDA center/program office, and list-removal or exemption criteria.
Yes. A firm or product can potentially be affected by multiple Import Alerts. Each alert and underlying violation should be reviewed separately, although FDA may sometimes allow related evidence to support more than one alert when the specific Guidance permits it.
A name change should not be treated as a removal strategy. FDA's public alert listing and underlying compliance information need to be corrected through appropriate regulatory channels, and the condition giving rise to DWPE still has to be addressed.
A representative may be able to submit a request, but the precise role of a U.S. Agent differs by FDA program. A food-facility U.S. Agent, drug U.S. Agent, device U.S. Agent, importer, attorney, or other representative should not be assumed to have identical authority in every case. The specific Import Alert and engagement should be reviewed.
Not as a universal Import Alert rule. Separate FDA programs can require a U.S. Agent for certain foreign registered facilities, but the requirement comes from the applicable registration program, not simply from filing a DWPE removal request.
Yes, when analytical evidence is relevant to the violation and the specific Import Alert. FDA's private laboratory guidance notes that lab reports can be useful for overcoming the appearance of a violation in appropriate DWPE cases. Some alerts have specific analytical or laboratory expectations.
Yes, in some cases. FDA's general removal guidance identifies third-party audits as an example of possible evidence, and some specific alerts expressly discuss inspection or audit information. Whether an audit is useful depends on the violation and alert.
Yes, for some alerts and violations FDA may determine that an inspection or other verification is necessary before considering the appearance of violation resolved. The specific Import Alert Guidance and responsible program office should be reviewed.
When an imported product is detained because it appears to violate FDA requirements, the importer of record may submit Form FDA 766 requesting permission to relabel or recondition the product in an attempt to bring that individual shipment into compliance (21 CFR 1.94). FDA can grant or deny the proposal.
No. Reconditioning concerns the admissibility of the individual detained shipment. It does not by itself remove a firm or product from DWPE under an Import Alert.
A business can offer shipments for import while DWPE remains in effect, but the entries remain subject to the applicable Import Alert. The importer should understand the Guidance section, evidence expectations, costs, and risks before continuing shipments.
FDA's Import Alert FAQ states that in most cases, publication of a firm/product on the Import Alert serves as notification to the firm.
Send the Import Alert number or link if known, firm and product name, country, FDA entry numbers, Notices of FDA Action, laboratory results, warning letters or inspection records, prior correspondence, corrective actions already taken, and any registration/listing or product documentation relevant to the cited issue.
Pricing is custom, and FDA itself charges no fee to file a removal petition. Scope depends on the Import Alert, product category, number of affected products or facilities, violation complexity, root-cause work, testing, audit or inspection evidence, clean-entry strategy, and level of FDA correspondence support required. Send the alert number for a written quote.
Yes. When useful, Import Alert removal work can be scoped together with FDA shipment monitoring, individual-entry detention assistance, laboratory or sampling coordination through our sister company, FDA Detention Sampling, FSVP, label correction, or other directly related compliance work. Any bundled pricing should be stated in the written quote rather than assumed.
The business should continue the corrective and preventive controls that supported the removal and verify its current status in the Import Alert database before future shipments. Removal from one Import Alert does not waive other FDA requirements or prevent future enforcement if new violations occur.
For covered food testing, yes. Testing to support removal from an import alert through successful consecutive testing is covered by the LAAF rule (21 CFR 1.1107), once FDA lists the analyte and the compliance date passes; see the FDA LAAF dashboard. Many current food import alerts now state that LAAF-accredited testing is required. Using a non-accredited lab can make clean-entry results unusable.
Tell us what your company makes, sells, or distributes, where each product is manufactured or packed, your U.S. importer or buyer arrangement, label readiness, and target shipment date.
Submitting this inquiry does not purchase a service or authorize paid work. Our team can discuss the scope and required materials before you commission assistance. Fields marked with an asterisk are required.